Naciye Güdük

Dr. Naciye Güdük

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
OBonur bas
onur bas
MTMert Tokatlı
Mert Tokatlı
NGNaciye Güdük
Naciye Güdük
DEDilara Erdoğan
Dilara Erdoğan
NBNur Evşan Boyraz
Nur Evşan Boyraz
SASercan Aksoy
Sercan Aksoy
Background: It is well known that supportive care clinics are vital in medical oncology practice. This study aims to present a portrait of the supportive care clinic of a tertiary cancer center in a low-middle-income country. Methods: This study included patients admitted to our supportive care clinic between January 2019 and December 2023. This study included patients who attended the supportive care clinic. For patients who were readmitted more than once throughout the study period, only the first readmission was included in the analysis. The primary outcome of this study was a better understanding of the risk factors associated with hospital readmissions in cancer patients, which could lead to improved patient outcomes. In addition, the secondary objective was to identify the characteristics of patients and clinical decisions regarding follow-ups as inpatients or outpatients referred to the supportive care clinic. Results: This study included 477 patients; 300 (62.9%) were directed to oncology inpatient care, while 177 (37.1%) were treated as outpatients. The most common diagnoses were lung cancer (20.5%), colorectal cancer (13.6%), and breast cancer (8.4%). Most patients (71.5%) were evaluated for symptom palliation. In multivariate analysis, metastatic disease (OR: 2.52 95% CI 1.48–4.29 p = 0.001), Eastern Cooperative Oncology Group (ECOG) performance status (OR: 1.58 95% CI 1.04–2.42 p = 0.034), and a decrease in albumin levels (OR: 0.42 95% CI 0.29–0.61 < 0.001) were significantly related to hospitalization. In univariate analyses, albumin level (p < 0.001), disease stage (p = 0.007), and ECOG performance status (p = 0.025) were statistically associated with unplanned hospital readmission. Among these factors, a decrease in albumin levels was significantly associated with the outcome, with an odds ratio of 0.54 (95% CI 0.39–0.75, p < 0.001), indicating a protective effect of higher albumin levels. In univariate analyses, sex (p = 0.016), cancer treatment type (p = 0.010), albumin level (p < 0.001), disease stage (p < 0.001), unplanned hospital readmission (p < 0.001), ECOG performance status (p < 0.001), and hemoglobin (p = 0.008) were statistically related to overall survival. Among these factors, sex (HR: 1.28 95% CI 1.03–1.59 p = 0.025), a decrease in albumin levels (HR: 0.67 95% CI 0.56–0.82 p < 0.001), disease stage (HR: 1.52 95% CI 1.11–2.09 p = 0.008), unplanned hospital readmission (HR: 1.30 95% CI 1.03–1.63 p = 0.027), and ECOG performance status (HR: 3.45 95% CI 2.68–4.45 p < 0.001) remained significant in the multivariate analysis. Conclusions: This study shows that supportive care clinics are a key element of patient care. Early evaluation of patients in supportive care clinics may aid clinicians in identifying high-risk patients who may require closer follow-up or inpatient care. Several factors were identified as predisposing to hospitalization, unplanned hospital readmission, and overall survival. Further prospective studies are needed to determine the risk factors associated with hospitalization, readmission, and overall survival.

Verified
Journal Article
Open access
PDF file
FKfatih kuş
fatih kuş
FSFirat Sirvan
Firat Sirvan
HYHasan Çağrı Yıldırım
Hasan Çağrı Yıldırım
IKIlgin Koc
Ilgin Koc
NGNaciye Güdük
Naciye Güdük
ZAZafer Arik
Zafer Arik
Background: Advanced-stage epithelial ovarian cancer is associated with variable survival outcomes, despite standardized treatments. Identifying reliable and accessible prognostic markers is critical to guide clinical decision-making. Objective: The aim of this study was to evaluate the prognostic significance of the modified Glasgow Prognostic Score (mGPS) in patients with FIGO stage III–IV epithelial ovarian cancer. Methods: In this retrospective cohort study, 89 patients diagnosed between 2018 and 2023 were analyzed. The mGPS was calculated from pre-treatment serum C-reactive protein (CRP) and albumin levels. Overall survival (OS) was assessed using Kaplan–Meier and Cox regression analyses. Results: The median OS was 32.3 months. When stratified by mGPS categories, the 2-year survival rates were 94%, 75%, and 34% in the mGPS 0, 1, and 2 groups, respectively (p < 0.001). In the multivariate Cox proportional hazards model, both mGPS (HR = 1.85; 95% CI: 1.12–3.07; p = 0.016) and ECOG performance status (HR = 1.67; 95% CI: 1.02–2.75; p = 0.043) were identified as independent predictors of overall survival. Conclusions: The mGPS is a simple, low-cost, and independently predictive tool for overall survival in advanced ovarian cancer. By capturing both systemic inflammation and nutritional status, it enhances risk stratification and may support individualized treatment planning. Prospective validation is warranted.

Verified
Journal Article
Open access
PDF file
OBonur bas
onur bas
NGNaciye Güdük
Naciye Güdük
MTMert Tokatlı
Mert Tokatlı
DGDeniz Can Guven
Deniz Can Guven
NÖNecla Özer
Necla Özer
ÖDÖmer Dizdar
Ömer Dizdar
Background: Several studies have suggested that the serum albumin–creatinine ratio (sACR) is a useful marker for the early risk stratification of patients with cardiomyocyte injury. This study aims to evaluate the relationship between sACR and anthracycline-related cardiotoxicity. Methods: This study included patients who had received anthracycline-based chemotherapy between 2014 and 2023 and had undergone baseline and follow-up echocardiography after the treatment. The level of sACR was calculated using serum albumin and creatinine values obtained before the chemotherapy. The definition of cardiotoxicity was based on the criteria of the European Society of Cardiology (ESC) for ejection fraction and the American Society of Echocardiography (ASE) for diastolic dysfunction. The patients were categorized into either the high or low sACR group based on the cut-off value obtained from the receiver operating characteristic (ROC) curve analysis. Results: In total, 525 patients (159 males, 366 females) were included. Multivariate analysis after adjustment for age, body mass index (BMI), cardiovascular disease, hemoglobin, anthracycline dose, and gender showed that sACR (HR = 1.85% 95 CI 1.12 to 3.06 p = 0.016), cardiovascular disease (HR = 1.97% 95 CI 1.08 to 3.61 p = 0.027), BMI (HR = 1.86% 95 CI 1.12 to 3.10 p = 0.017), and age (HR = 1.02% 95 CI 1.001 to 1.04 p = 0.036) were significantly associated with an increased risk of cardiotoxicity. Conclusions: This study is the first to show a significant relationship between sACR and cardiotoxicity related to anthracycline use. Routine laboratory tests that are conducted before anthracycline therapy can aid clinicians in identifying high-risk patients who may require closer follow-up or cardioprotective measures.

20 June 2025 in Acta Medica
Verified
Journal Article
Open access
PDF file
OBonur bas
onur bas
MTMert Tokatlı
Mert Tokatlı
NGNaciye Güdük
Naciye Güdük
LKLatif Karahan
Latif Karahan
TSTaha Koray Sahin
Taha Koray Sahin
SASercan Aksoy
Sercan Aksoy
Background: The objective of this study is to assess the correlation between survival outcomes and fibrosis-4 (FIB-4) index in patients with non-metastatic breast cancer treated with anthracyclines Methods: This study was conducted on individuals with non-metastatic breast cancer who were treated with at least one dose of anthracycline from 2018 to 2023. The FIB-4 index was calculated based on the following parameters: age, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels, and platelet count for each patient before anthracycline treatment. Results: A total of 208 patients were included in the study. Patients below 35 years of age (n=28) and those above 65 years of age (n=11) were excluded from the study as the FIB-4 index is less reliable in these age groups. Patients were then divided into two subgroups, low and high, according to the pre-defined cut-off value of 1.45, which is obtained from the primary reference. In univariate analysis, hemoglobin (p=0.03), FIB-4 index (p=0.02), and diagnosis at stage (p=0.01) were statistically related to overall survival (OS). In multivariate analysis, patients with higher FIB-4 index (HR: 4.36, 95% CI 1.38-13.78 p=0.012), anemia (HR: 3.32, 95% CI 1.32-8.34, p=0.011), and stage 3 (HR: 4.53, 95% CI 1.22-16.76, p=0.024) had decreased OS. An additional aim was to evaluate the association between anthracycline-induced cardiotoxicity and the FIB-4 index. Our study showed no relationship (p=0.738). Conclusions: The FIB-4 index, a marker easily obtained through routine biochemistry testing at low cost, could serve as an independent predictor of OS patients with non-metastatic breast cancer treated with anthracyclines. Routine lab tests performed for cancer patients may help clinicians identify high-risk patients in whom closer follow-up or protective measures should be considered.

31 August 2025 in Journal of Medicine and Palliative Care
Verified
Journal Article
Open access
OBonur bas
onur bas
NGNesime İnCi Güner
Nesime İnCi Güner
MTMert Tokatlı
Mert Tokatlı
NGNaciye Güdük
Naciye Güdük
TSTaha Koray Sahin
Taha Koray Sahin
SASercan Aksoy
Sercan Aksoy
Aims: Management of bone metastasis is crucial for cancer patients. The objective of this study was to assess the correlation between survival outcomes and bone-modifying agents (BMAs) in patients treated with immune checkpoint inhibitors (ICIs). Methods: This study was conducted in individuals who received at least 3 doses of ICIs between January 2018 and December 2023 and had bone metastases at initiation of ICIs. We retrospectively collected data on each patient from their medical records, including information on cancer, the specific immunotherapy treatment, and the BMAs they were receiving. Results: 142 patients were included. The median follow-up was 36 [interquartile range (IQR)=18-50] months and the median follow-up from the initiation of BMAs to the last control was 14 months (IQR=5-29). After adjustment for age, gender, Eastern Cooperative Oncology Group (ECOG) score and number of prior treatment lines in the multivariate analyses, patients who did not use BMAs had decreased overall survival (OS) (HR: 2.30, 95%CI: 1.03-2.45; p=0.036). In addition, BMAs use was associated with long-term benefit defined as having a survival of equal to or longer than 24 months (HR: 2.85, 95%CI 1.13-7.21; p=0.027). Conclusion: It was found that using BMAs could be an independent predictor of OS in patients treated with ICI and who had bone metastasis. This finding may lead clinicians to start BMAs as soon as possible after bone metastases are detected.

29 September 2026 in İç Hastalıkları Dergisi
Verified
Journal Article
Closed access
OUOğuz Abdullah Uyaroğlu
Oğuz Abdullah Uyaroğlu
MTMert Tokatlı
Mert Tokatlı
YYYiğit Yazarkan
Yiğit Yazarkan
ATAdem Tutuş
Adem Tutuş
DSDilara Erdoğan Sivri
Dilara Erdoğan Sivri
GGGülay Sain Güven
Gülay Sain Güven